Floatz logo

FULVESTRANT

Hormone Receptor Positive Tumor

Relay Therapeutics, Inc.Small moleculePhase 3Active
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
60/ 100
Competitive Position
89/ 100

Competitive context

91 Active assets in the Hormone Receptor Positive Tumor cohort.

Asset / SponsorPhaseRating
Abemaciclib
Relay Therapeutics, Inc.
Phase 2BB
Palbociclib
Relay Therapeutics, Inc.
Phase 2BB
Letrozole
Relay Therapeutics, Inc.
Phase 2BB
Ribociclib
Relay Therapeutics, Inc.
Phase 3BB
Capecitabine
Fudan University
Phase 3BB

View all 50 →

Same molecule, other indications

FULVESTRANT is also rated in:

hormone receptor-positive breast cancerDormant
BB
Indicative ·
70 / 100
View asset →
Progesterone Receptor PositiveDormant
BB
Indicative ·
69 / 100
View asset →
invasive breast carcinomaDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →